Advanced Bladder Cancer VL

Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo

Details
In this UroToday discussion between Petros Grivas, MD, PhD, Guru Sonpavde, MD, and Maria Carlo, MD, the trio discuss recent publications on germline testing and genetic profiling. The conversation kicks off with a background on Dr. Carlo’s recent work concerning genetic testing for urothelial and bladder cancer patients. The conversation shifts to hear from Dr. Sonpavde about his recent work in lo...

Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 Journal Club – Christopher Wallis & Zachary...

Details
In this UroToday GU Oncology Journal Club, Christopher Wallis and Zachary Klaassen highlight a Journal of Clinical Oncology publication on a phase two open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma, progressing after platinum-based chemotherapy and checkpoint inhibitors. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With M...

Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt

Details
In this UroToday discussion between Alicia Morgans and Samuel Funt, they discuss Samuel Funt’s recent phase 2 trial evaluating the use of atezolizumab, with gemcitabine and cisplatin, as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). The conversation begins with background on the study, beginning with Dr. Funt’s description of neoadjuvant cisplatin-based chemotherapy as the standar...

Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma – Terence W. Friedlander

Details
In this discussion, Alicia Morgans and Terence Friedlander discuss updates from the EV-103 study. The EV-103 study is a phase one/two clinical trial that looked at the combination of enfortumab vedotin and pembrolizumab in, previously treated, patients with cisplatin-ineligible, metastatic urothelial cancer. Historically, cisplatin-ineligible metastatic urothelial cancer patients have had a very p...

Updated Results from EV-201 Cohort 2 - Enfortumab Vedotin Is A Potential Non-Platinum Option for Cisplatin-Ineligible Patients Following Anti-PD-1/L1 Treatment - Bradley McGregor

Details
Cisplatin chemotherapy is the standard of care for medically fit patients in advanced urothelial carcinoma. Unfortunately, up to 50% of these patients are medically ineligible for cisplatin due to low-performance status, renal dysfunction, or other medical comorbidities. Immune checkpoint blockade is a first-line therapeutic option in either platinum ineligible patients or carboplatin eligible pat...

Advances in the Treatment of Metastatic Urothelial Cancer - Matthew Galsky

Details
Several Phase III trials have read out in the first-line treatment of metastatic urothelial cancer in the past few years. In a discussion with Ashish Kamat, Matthew Galsky discusses the expanse in clinical data in metastatic urothelial cancer shaping the treatment landscape. Guiding this conversation, Matthew Galsky focuses on 4 main take-home points and shares optimism in potential development to...

Intersection of Biology and Clinical Characteristics Towards Personalized Sequential Treatments for MIBC - Andrea Necchi and Ewan Gibb

Details
A transurethral resection of bladder tumor (TURBT), followed by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) is a standard-of-care therapy for muscle-invasive bladder cancer (MIBC). Andrea Necchi, a medical oncologist, and Ewan Gibb a researcher at Decipher Biosciences join Alicia Morgans to discuss a study that expands our understanding of the biology of pembrolizumab-resistant musc...

TROPHY-U-01 Results Lead to Accelerated Approval of Sacituzumab Govitecan (Trodelvy) for Pretreated Metastatic Urothelial Carcinoma - Scott Tagawa

Details
Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govitecan (Trodelvy) is a TROP-2–directed antibody-drug conjugate with an SN-38 payload that has shown pr...

Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal

Details
In this conversation, Alicia Morgans, MD MPH, Neeraj Agarwal, MD, and Petros Grivas, MD, PhD discuss the clinical trial findings from the JAVELIN Bladder 100 trial and how-to treat with chemotherapy followed by avelumab maintenance. They highlight the importance of this to the treatment algorithm of metastatic urothelial carcinoma and highlight a recent publication in Cancer Treatment Reviews on a...

Voluntary Withdrawal In The US of Durvalumab and of Atezolizumab in Metastatic Urothelial Carcinoma - Petros Grivas

Details
In February 2021 AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. In March 2021, Genentech announced the voluntary withdrawals of Tecentriq® (atezolizumab) for the treatment of prior-platinum treated metastatic urothelial carcinoma. Petros Grivas and Alicia Morga...